GlassScriptPhysician profile
Elvin G Ruiz
NPI 1568538379
$19,202.55
in general payments reported to CMS, 2019-2025
34 companies · $1,993 in 2025
The $1,993 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,368 · 2020: $1,848 · 2021: $3,238 · 2022: $3,306 · 2023: $4,491 · 2024: $1,959 · 2025: $1,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,163 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,162.56 |
| Education | $279.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,473.88 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,515.80 | 2019-2025 | Trintellix |
| Neos Therapeutics, LP | $1,474.09 | 2019-2024 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $1,449.53 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,205.33 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,180.96 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $938.97 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $894.38 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $891.92 | 2019-2020 | |
| Alkermes, INC. | $868.24 | 2022-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $728.77 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Tris Pharma INC | $674.96 | 2023-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $615.82 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $469.67 | 2019-2023 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $452.90 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $440.62 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $404.81 | 2019-2023 | Spravato |
| Harmony Biosciences LLC | $219.97 | 2022-2025 | |
| Brainsway USA INC | $207.55 | 2019-2025 | Deep Tms System |
| Almatica Pharma LLC | $204.90 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $169.35 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $119.50 | 2025 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $104.17 | 2019-2020 | |
| Pfizer INC. | $96.46 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $80.48 | 2021 | |
| Azurity Pharmaceuticals, INC. | $60.41 | 2023-2024 | Horizant, Horizant |
| Bausch Health US, LLC | $41.27 | 2019-2024 | Wellbutrin, Aplenzin |
| Aytu Biopharma, INC. | $41.11 | 2021 | |
| Collegium Pharmaceutical, INC. | $40.65 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $38.18 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $35.19 | 2025 | Fanapt |
| Amgen INC. | $25.35 | 2019 | |
| Sumitomo Pharma America, INC. | $21.36 | 2023 | Latuda |
| Noven Therapeutics, LLC | $16.00 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elvin Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.